Atherectomy

WASHINGTON — In patients with severely calcified coronary lesions eligible for either treatment, orbital atherectomy did not improve clinical or imaging outcomes compared with conventional balloon angioplasty, researchers reported.

AngioDynamics announced its 225 cm radial access catheter for use with the company’s atherectomy system received FDA 510(k) clearance for the treatment of peripheral artery disease.

Directional (Hawkone, Medtronic) vs. orbital (Diamondback 360, Cardiovascular Systems Inc.) atherectomy system on athero-sclerotic plaque in peripheral artery disease.

AngioDynamics announced it received an FDA clearance of an expanded indication for its atherectomy system to include arterial thrombectomy.

In adults with peripheral arterial disease, a directional atherectomy system significantly reduced vessel stenosis and plaque burden vs. an orbital atherectomy system, even after drug-coated balloon treatment, researchers reported.

1-year extension study assessing early (STEP 1) or late (STEP 2) clinician education intervention to improve achievement of LDL goals.

Medtronic is recalling its HawkOne Directional Atherectomy System due to risk for the tip of the catheter becoming damaged during use, which may include the catheter tip breaking off or separating, according to an FDA press release.

Cardiovascular Systems Inc. announced a recall of its embolic protection device due to complaints of filter breakage during retrieval of lower limb blood clots associated with atherectomy procedures in lower limbs.

A strategy of directional atherectomy followed by drug-coated balloon treatment was beneficial in patients with long, calcified femoropopliteal lesions, according to 12-month results of the REALITY study.

Recently, there has been renewed interest in the treatment of higher-risk patients undergoing PCI for complex CAD. Novel techniques and equipment have expanded operators’ ability to treat patients with increasingly complicated lesion types.